Paying for Cures Webinar: Could the new CMS Rule on Medicaid Best Price make gene therapy value-based pricing common?
NPC's Michael Ciarametaro will join an expert panel to discuss one of the biggest challenges to new financing models for innovative therapies: the new CMS rule on Medicaid Best Price.
Could the new CMS Rule on Medicaid Best Price make gene therapy value-based pricing common?
Panel Discussion and Q&A | Webinar | July 21, 2022 11:00 a.m - 12:00 p.m. ET
Durable, potentially curative cell and gene therapies with short-term treatment regimens promise to transform care for some conditions, but present significant financial risks and uncertain long-term efficacy.
One of the biggest challenges to new financing models for innovative therapies is the 1990 Medicaid "best price" rules, which ensures that the Medicaid program receives discounts at least as large as commercial payers. But CMS is implementing a new rule in January 2023 for tiered MBP reporting based on performance.
Important questions about implementation, participation, and pricing persist. Join NPC's VP of Research, Michael Ciarametaro, and other expert panelists to bring both quantitative analysis and practical experience perspectives to bear on the issues.
In this one-hour webinar you will:
- Explore the use of alternative payment approaches to managing financial risk associated with curative therapies
- Learn how the new CMS rule could lead to widespread feasibility and adoption of Value-Based Purchasing Arrangements
- Learn what challenges remain and how they can be overcome by a combination of clever implementation and eventually, legislative enhancements to the Medicaid Drug Rebate Program
Ideal for:
- Biopharmaceutical market access and government affairs
- Payer pharmacy benefits and contracting
- Employer benefits managers and benefits consultants
- Specialty pharmacy and channel intermediaries
- Policymakers
- Patient advocates
- …and all those interested in drug payment innovation
Registration Information:
Panelists
• Mark Trusheim, MS, Strategic Director, NEWDIGS, and Visiting Scientist, Sloan School of Management, Massachusetts Institute of Technology (Moderator)
• Michael Ciarametaro, MBA, Vice President, Research, National Pharmaceutical Council
• Dorothy Hoffman, MPP, External Engagement and Access Policy Lead, Healthcare Innovation Center, Pfizer
• Gail Ryan, PharmD, Director, Pharmaceutical Transformation, Clinical Innovation, Point32Health (Harvard Pilgrim Health Care & Tufts Health Plan)
